CymaBay Therapeutics has received a patent to treat NAFLD and NASH with MBX-0825
by administering an amount that proves to be therapeutically effective orally.
The coverage provided by the lasts until 2035.
“This
patent provides CymaBay with important additional intellectual property
protection for MBX-8025, expanding it to the treatment of NASH, a disease with
increasing prevalence and no currently approved therapies,” CymaBay’s CEO and President Harold Van Wart said.
CymaBay Therapeutics has received a patent to treat NAFLD
Alerts Sign-up